Efficacy and safety of anti ‐PD ‐1/ PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis-Reference-Cited by-同舟云学术

Efficacy and safety of anti ‐PD ‐1/ PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis

Published:2021-12-14 Issue:3 Volume:13 Page:322-337
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Wang Liming¹²,Yang Yifan²³,Yu Jiangyong²,Zhang Shuai²,Li Xu²,Wu Xiaonan²,Nie Xin²^ORCID,Liu Wenbo²,Zhang Ping²,Li Yi²,Li Ailing⁴,Ai Bin¹²^ORCID

Affiliation:

1. Beijing Hospital, National Center of Gerontology Beijing P.R. China

2. Department of Medical Oncology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing P.R. China

3. Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P.R. China

4. Institute of Microcirculation, Peking Union of Medical College & Chinese Academy of Medical Science Beijing P.R. China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14244

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

3. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology